Navigation Links
TorreyPines Therapeutics Announces its Board of Directors' Approval of Plan of Liquidation and Dissolution
Date:5/29/2009

DDITIONAL INFORMATION HAS BEEN FILED WITH THE SEC.

This press release is for informational purposes only. It is not a solicitation of a proxy. In connection with the Plan of Dissolution, the Company has filed with the Securities and Exchange Commission a proxy statement and other relevant materials. THE COMPANY'S STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT AND THE OTHER RELEVANT MATERIALS BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY AND THE PLAN OF DISSOLUTION. Stockholders may obtain a free copy of the proxy statement and the other relevant materials and any other documents filed by the Company with the SEC, at the SEC's web site at http://www.sec.gov. In addition, the Company will mail a copy of the definitive proxy statement to stockholders of record on the record date for the special meeting of stockholders which has yet to be determined. A free copy of the proxy statement and other documents filed with the SEC by the Company may also be obtained by directing a written request to: TorreyPines Therapeutics, Inc., Attn: Secretary, 11085 North Torrey Pines Road, La Jolla, CA 92037, or by accessing the "Investor Relations" section of the Company's website at www.tptxinc.com. Stockholders are urged to read the proxy statement and the other relevant materials before making any voting or investment decision with respect to the Plan of Dissolution.

About TorreyPines Therapeutics, Inc.

TorreyPines Therapeutics, Inc. is a biopharmaceutical company which has been committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal has been to develop versatile product candidates each capable of treating a number of acute and chr
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. TorreyPines Therapeutics Reports Third Quarter 2007 Results
7. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
8. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
9. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
10. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
11. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... DUBLIN , July 31, 2014 ... the "Global Genomics Market 2014-2018" report to ... Genomics is the study of the genetic ... to be a strong basis for the discovery and ... of human diseases or health conditions. Genomics is supported ...
(Date:7/31/2014)... 2014 Senomyx , Inc. (NASDAQ: ... proprietary taste science technologies to discover, develop, and ... and ingredient supply industries, today reported financial results ... the second quarter with $33.6 million in cash ... the past quarter Senomyx achieved another important milestone ...
(Date:7/31/2014)... SHENZHEN, China , July 31, 2014 /PRNewswire/ ... of an Irys™System by BGI , ... to enable comprehensive exploration of human structural variation (SV) ... of interest, including those where no reference exists. In ... new methods for multiplexing on the Irys System, enabling ...
(Date:7/31/2014)... Rancho BioSciences , the scientific data ... Suite with tranSMART . Scientists that have ... data in tranSMART to Array Suite for further analysis. ... including the new 1.2 release. Array Suite provides ... the analysis of high dimensional quantification data, including expression, ...
Breaking Biology Technology:Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16BioNano Genomics Announces the Purchase of the Irys System by BGI 2BioNano Genomics Announces the Purchase of the Irys System by BGI 3BioNano Genomics Announces the Purchase of the Irys System by BGI 4Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 2Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 3
... Madison, Wis. - Jason Smith acknowledges he's on a personal ... sector fund of the Peak Ridge Capital Group, wants to bridge ... and his passion for investing in innovative Midwestern technology companies is ... wake up in the morning and it is one of the ...
... of Commerce has qualified seven small businesses for ... Venture Fund Tax Credit programs. , ,The programs, ... biotechnology companies, offer Wisconsin income tax credits to angel ... that invest in qualified businesses can claim tax credits ...
... - Jeff Cason is preparing to expand his company ... victory. , ,As founder of JT Packard & Associates, ... provider. The company has grown by 500 percent over the ... supply (UPS) service company in the country by a factor ...
Cached Biology Technology:Investor links East Coast funds to Midwest tech 2Investor links East Coast funds to Midwest tech 3Commerce qualifies seven for investor tax credits 2Power services firm JT Packard isn't through growing 2Power services firm JT Packard isn't through growing 3
(Date:7/31/2014)... U.S. Census Bureau, Latinos are the largest minority group ... Approximately one-third of Latinos are obese and are ... non-Hispanic Whites. , NYU College of Nursing student ... to identify the factors that contribute to this problem ... focused on food patterns in Latina women recently published ...
(Date:7/31/2014)... follow-up study (HPV-023; NCT00518336) shows the sustained ... papilloma virus (HPV) vaccine Cervarix. Women vaccinated ... for more than nine years, and vaccine ... This is the longest follow-up report for ... for the full paper. , ...
(Date:7/31/2014)... from Spain, France, and the U.S. has discovered ... oldest definitive member of the tribe Omaliini that ... and description were made possible through the use ... which allows the detailed study of otherwise invisible ... described in the journal Annals of the ...
Breaking Biology News(10 mins):NYU research looks to combat US Latina immigrant obesity 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3
... University] One of biggest factors promoting the diversity of ... to new research by ecologists at Brown University. Experiments and ... the flow, the greater the number of invertebrate species that ... the week of Nov. 15 in the journal Ecology ...
... have found a potential genetic target for heart disease, ... of the nation,s No. 1 killer in its initial ... first time at the American Heart Association,s (AHA) Scientific ... by WenFeng Cai, PhD, a postdoctoral fellow under the ...
... including commercial bathroom disinfectants and over-the-counter fungicides used ... battle against a strange fungus that threatens bat populations ... article in the current issue of Chemical & Engineering ... Correspondent Stephen K. Ritter notes that despite their poor ...
Cached Biology News:Faster water flow means greater diversity of invertebrate marine life 2Researchers discover potential genetic target for heart disease 2
... is a trademark of Merck KGaA. Physical form: Solution ... 8.0, 2 mM MgCl 2 , and 20 mM ... herring sperm DNA to acid-soluble oligonucleotides equivalent to a ... pH 8.0 at 37 C (reaction volume 2.625 ml). ...
Mouse monoclonal antibody to PPP2R2C - protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), gamma isoform...
Mouse monoclonal antibody to PARK2 - Parkinson disease (autosomal recessive, juvenile) 2, parkin...
... used to quantitate double-stranded DNA (dsDNA) in solution, ... With this kit, DNA is stained with Hoechst ... VersaFluor or other fluorometer. The kit quantitates dsDNA ... to 5 micrograms per ml and contains Hoechst ...
Biology Products: